CNS Clinical Trials: Suicidality and Data Collection: Workshop Summary
Book information
Description
The Food and Drug Administration (FDA) now requires that all clinical trials for drugs that affect the central nervous system--including psychiatric drugs--are assessed for whether that drug might cause suicidal ideation or behavior. The Institute of Medicine's (IOM) Forum on Neuroscience and Nervous System Disorders hosted a meeting on June 26, 2009, to discuss the FDA's new policy and how to analyze best whether suicidal thoughts predict actual suicidal behavior in the near future.
Similar books
Improving the Utility and Translation of Animal Models for Nervous System Disorders: Workshop Summary
2013 · PDF
Neurodegeneration: Exploring Commonalities Across Diseases: Workshop Summary
2014 · PDF
Glutamate-Related Biomarkers in Drug Development for Disorders of the Nervous System: Workshop Summary
2011 · PDF
Venture Philanthropy Strategies to Support Translational Research: Workshop Summary
2009 · PDF
Mental, Neurological, and Substance Use Disorders in Sub-Saharan Africa: Reducing the Treatment Gap, Improving Quality of Care: Workshop Summary
2010 · PDF
MySQL® Notes for Professionals book
2018 · PDF
MrExcel 2022: Boosting Excel
2022 · PDF
MrExcel 2022: Boosting Excel
2022 · PDF